EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial

Julien Taieb, Dominik P Modest, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Elez, Cristina Gravalos, Arinilda Campos Bragagnoli, Valentine Barboux, Lucas Roby, Nadia Amellal, Gerald W Prager

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115644 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Julien Taieb und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Gastrointestinal Oncology, CARPEM Comprehensive Cancer Center, Georges-Pompidou European Hospital, AP-HP, Universi…. Hauptthemen laut MEDLINE: Trifluridine, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Servier.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrifluridineColorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansBevacizumabMaleFemalePyrrolidinesThymineAgedMiddle AgedDrug CombinationsTumor BurdenUracilAdultTreatment OutcomeAged, 80 and overNeoplasm Metastasis

Stichwörter der Autor:innen

BevacizumabColorectal cancerDepth of responseResponse parametersTrifluridine/tipiracil

Substanzen

BevacizumabTrifluridinePyrrolidinesThyminetrifluridine tipiracil drug combinationDrug CombinationsUracil

Autor:innen und Institutionen

  • Department of Gastroenterology and Gastrointestinal Oncology, CARPEM Comprehensive Cancer Center, Georges-Pompidou European Hospital, AP-HP, Université Paris-Cité, Paris, France; Centre de Recherche des Cordeliers, INSE…
  • Department of Hematology, Oncology and Cancer Immunology (CVK), Charité-Universitaetsmedizin, Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, German Cancer Research Centre (DKFZ), Heidelberg, Germ…
  • City of Hope Comprehensive Cancer Center, Duarte, USA.
  • Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy.
  • University Hospitals Gasthuisberg and University of Leuven (KUL), Leuven, Belgium.
  • Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), UVic-UCC, Barcelona, Spain.

Förderung

  • Servier

Zitieren

APA

Taieb, J., Modest, D. P., Fakih, M., Ciardiello, F., Van Cutsem, E., Elez, E., Gravalos, C., Bragagnoli, A. C., Barboux, V., Roby, L., Amellal, N., & Prager, G. W. (2025). Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115644

Vancouver

Taieb J, Modest DP, Fakih M, Ciardiello F, Van Cutsem E, Elez E, et al. Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115644

BibTeX
@article{Taieb2025,
  author = {Taieb, Julien and Modest, Dominik P and Fakih, Marwan and Ciardiello, Fortunato and Van Cutsem, Eric and Elez, Elena and Gravalos, Cristina and Bragagnoli, Arinilda Campos and Barboux, Valentine and Roby, Lucas and Amellal, Nadia and Prager, Gerald W},
  title = {Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115644}
}
Kostenlos starten →